(Q44237254)

English

How to determine post-FCR therapy for cytogenetic risk-tailored elderly patients with chronic lymphocytic leukemia, maintenance rituximab or observation

scientific article published on 2 July 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

How to determine post-FCR therapy for cytogenetic risk-tailored elderly patients with chronic lymphocytic leukemia, maintenance rituximab or observation (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Bin-Tao Huang

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Qing-Chun Zeng

2

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Wei-Hong Zhao

3

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Bing-Sheng Li

4

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Rui-lin Chen

5

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

publication date

2 July 2014

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Medical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

104

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0104-7

21 January 2018

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0104-7

21 January 2018

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0104-7

21 January 2018

Therapy of elderly/comorbid patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0104-7

21 January 2018

Chronic lymphocytic leukemia: an update on biology and treatment.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0104-7

21 January 2018

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0104-7

21 January 2018

Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0104-7

21 January 2018

Maintenance in CLL.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0104-7

21 January 2018

Cancer treatment and survivorship statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0104-7

21 January 2018

How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0104-7

21 January 2018

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0104-7

21 January 2018

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0104-7

21 January 2018

An update on the management of chronic lymphocytic leukaemia.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0104-7

21 January 2018

How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0104-7

21 January 2018

Standard intensive chemotherapy is less effective and far more toxic than attenuated induction and post-induction regimen in elderly patients with acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0104-7

21 January 2018

Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network

1 reference

https://pubmed.ncbi.nlm.nih.gov/24985882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/24985882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fludarabine in the treatment of chronic lymphocytic leukemia: a review

1 reference

https://pubmed.ncbi.nlm.nih.gov/24985882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of advanced chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/24985882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network

1 reference

https://pubmed.ncbi.nlm.nih.gov/24985882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of rituximab in first-line treatment of chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/24985882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12032-014-0104-7

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44237254&oldid=2206517930"